Skip to content

Optimization of lipid nanoparticle components and microfluidic parameters for intramuscular circRNA delivery with reduced hepatic off-targeting.

Sep 2026 · Lab on a Chip · 0 citations
Medicine

TL;DR

This study successfully develops an optimized formulation with reduced hepatic off-target effects, which holds great promise for the intramuscular delivery of circRNA-based vaccines and therapeutics.

Abstract

Circular RNA (circRNA) represents a promising class of RNAs for sustained protein expression and vaccine applications. However, current lipid nanoparticle (LNP) platforms remain poorly optimized for efficient intramuscular circRNA delivery, as they are primarily designed for the delivery of small interfering RNA and linear messenger RNA with strong off-target expression in the liver. In this study, based on the clinical benchmark SM-102 LNP, we systematically optimized lipid components and microfluidic parameters for better intramuscular circRNA delivery. Through in vitro and in vivo screening of a variety of phospholipids and sterols, we identified a 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)- and cholesterol-based formulation, which demonstrated improved storage stability and enhanced intramuscular transfection while minimizing hepatic off-target expression. Using ovalbumin as a model antigen, we proved that this formulation-based vaccine elicited more balanced Th1/Th2 immune responses with reduced liver toxicity. Together, this study successfully develops an optimized formulation with reduced hepatic off-target effects, which holds great promise for the intramuscular delivery of circRNA-based vaccines and therapeutics.

View source

Similar papers

Review Open access Oct 2026

Recent advances in the use of lipid nanoparticles (LNPs) as delivery vectors for mRNA

Therapeutic mRNA has demonstrated great promise in infectious disease vaccines, cancer immunotherapy, and protein replacement therapies. However, its clinical translation is hampered by intrinsic limitations, including rapid degradation, poor membrane permeability, extremely low endosomal escape, lack of tissue spe...

Jian-Mei Li, Wen-Ling Wu, Jie Dai et al. · 0 citations
Open access 2027

Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Components for Genome Editing.

This protocol describes a standardized microfluidic workflow for reproducible LNP formulation, providing practical guidance on lipid preparation, nanoparticle assembly, and quality control.

A. Olsen, C. Brandt, Rasmus Karred Larsen et al. · 0 citations
Sep 2026

Tailoring lipid nanoparticles for application-specific mRNA delivery.

This study proposes an application-oriented re-engineering strategy that leverages the clinically validated SM-102 platform, enabling rational LNP optimization for diverse mRNA delivery and therapeutic scenarios and recommends SM-102/DSPC and SM-102/DOPE LNPs as preferred formulations for RAW 264.7 macrophages and IGRO...

Xin-Xin Yan, Li-Xin Lin, Yi-Fan Zhang et al. · 0 citations
Review Open access Oct 2026

Emerging Lipid Nanoparticle Targeting Strategies for Extrahepatic Delivery of RNA Therapeutics.

Lipid nanoparticles (LNPs) have transformed RNA therapeutics through their high delivery efficiency, scalable manufacturing, and favorable safety profiles, as demonstrated by COVID-19 mRNA vaccines and clinically approved small interfering RNA (siRNA) therapeutics. However, extending RNA delivery beyond the liver to ex...

Jia-Xin Li, Jian-Ping Liu, Nan Wang et al. · 1 citation
Sep 2026

Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles.

Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.

Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay et al. · 0 citations
Open access Sep 2026

Protein Corona Engineering of Lipid Nanoparticles Enables Efficient Functional Gene Silencing in the Liver.

Lipid nanoparticles (LNPs) preferentially accumulate in the liver, but hepatic tropism alone does not ensure productive RNA interference. Here, we screened a library of LNPs in which lipid composition was varied to generate distinct protein corona identities and identify formulations capable of combining liver accumula...

N. G. Sukubo, Serena Renzi, M. Violatto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.